

**EISAI RECEIVES MANUFACTURING AND MARKETING AUTHORIZATION
FOR VASCULAR EMBOLIZATION DEVICE DC BEAD® IN JAPAN**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has

[Notes to editors]

1. DC Bead® Outline

The DC Bead is a hydrophilic microspherical particle produced from a cross-linked polyvinyl alcohol polymer. It is an embolic bead that is injected through a catheter to selectively embolize targeted blood vessels. As the device is microscopic and uniformly spherical, it allows for sustained embolization of targeted vessels based on vascular diameter and tumor size. The embolization material contained in the device has been confirmed by endoscopic observation to cause blood clotting in targeted blood vessels. Following its regulatory approval in Japan, the product will be made available in three particle sizes (100-300 µm, 300-500 µm, and 500-700 µm) so that a suitable particle size can be selected based on vascular diameter, tumor size and the extent of intended embolization in the targeted blood vessel.

In addition to the DC Bead's currently approved indication in Japan for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC), Eisai is currently also carrying out Phase III clinical trials of the device as an effective embolization material for treating other hypervascularized tumors in Japan.

2. About Transcatheter Arterial Embolization (TAE)

TAE is a therapy that selectively obstructs blood circ